Laboratory research

Our Partners

ORIGIN brings together a highly multidisciplinary consortium of leaders in their respective fields (academia and industry with photonics, engineering, medical physics, radiobiology, and clinical expertise), in order to develop a new 16 point array optical fibre dosimeter for both LDR- and HDR-BT, with novel algorithms to provide 3D dose imaging with source localisation capability. The involvement on both industry and clinical partners from the outset will ensure that patient care is at the forefront across the entire value chain. The integration of the ORIGIN system within existing clinical treatment planning systems and after-loader delivery devices will provide enhanced adaptive therapy, for improved patient outcomes.
Life science research


Partners role

UL Coordinator. Integration of the hardware components for the LDR and HDR ORIGIN systems. Software development for dose imaging and source localisation.
UNINS Development of the photon detector array for optical signal control and acquisition
VUB Redesign of the LDR- and HDR-BT probes for improved optical performance and compliance with spatial resolution requirements; prototype fabrication and demonstration of repeatable high-volume manufacturability
BME System integration with existing clinical BT delivery devices and advise on regulation and marketability
QUB End-user. system requirements, validation of the optical fibre based dose imaging and source localisation systems and protocol development. Development of semi-anatomical phantoms. Clinical integration of the ORIGIN system.
GC End-user. system requirements, validation of the optical fibre LDR-BT dose imaging and source localisation systems and protocol development
FINBA/HUCA End-user. system requirements, validation of the optical fibre based dose imaging and source localisation systems and protocol development


Our Partners


University of Limerick (UL)

The University of Limerick (UL) with over 13,000 students and 1,300 staff is an energetic and enterprising institution with a proud record of innovation and excellence in education, research and scholarship. The dynamic, entrepreneurial values which drive UL’s mission and strategy ensure that we capitalise on local, national and international engagement and connectivity.

Research at UL is renowned for its close alignment to real world problems and the university has an enviable reputation in fundamental research, which can have real impact on society and the economy alike. This strong focus allowed UL to gain a five star rating for innovation and excellence from QS, the international ranking body. This close alignment has also allowed UL to successfully compete for and win the right to host 5 national centres of excellence, all of whom have significant industry involvement, and aim to tackle real world issues. UL has a strong international reach and Involvement in the European Framework actions from FP2 to FP7, and current involvement in Horizon 2020 has grown UL’s international network of collaborators.

The project will be hosted by Optical Fibre Sensors Research Centre (OFSRC), one of nine research centres within the Electronic & Computer Engineering Department, College of Science and Engineering. Established in 1997 by Director Prof. Elfed Lewis, the OFSRC has been engaged in numerous national, European funded and industry collaborative projects in the general area of optical sensors for environmental, medical and industrial process monitoring. The Optical Fibre Sensors Research Centre currently occupies a laboratory which is 75m2 in area and has extensive optical test and calibration equipment including fusion splicer, optical attenuation test, OTDR, spectrometer, and stabilised sources.


Vrije Universiteit Brussel (VUB)

Vrije Universiteit Brussel (VUB) belongs to the UNICA Network of Universities of the Capitals of Europe. In ORIGIN, VUB is represented by Brussels Photonics (B-PHOT), which is a research and innovation group within the Faculty of Engineering of VUB. VUB B-PHOT’s staff consists of a total of 59 collaborators, whose photonic R&I activities are coordinated by Prof. Hugo Thienpont. VUB B-PHOT is internationally recognized for its fundamental, strategic and applied research in the field of photonics and is also uniquely involved in industry-related photonics innovation projects in the Flanders Region and Europe. VUB B-PHOT has more than 30 years of experience in photonics-enabled research and more than 20 years in photonics-enabled innovation. Today VUB B-PHOT focuses its research and innovation actions on six topical areas: freeform optical systems, optical fiber sensing, photonic-enhanced lab-on-chip, optical spectroscopy, semiconductor lasers, and nonlinear photonic integrated circuits. VUB B-PHOT’s advanced in-house technology, metrology, and demonstrator platforms for the fabrication, testing, and replication of plastic and glass optical components, wafer-scale lab-on-chips, and optical fiber-sensors are accessible to national and international collaborative research groups for interdisciplinary research and innovation in the topical areas of e.g. food-safety, biotechnology, advanced manufacturing, textile, secure data communication, archaeometry, and many more. VUB B-PHOT strongly collaborates with companies in photonics-enabled innovation projects that span a variety of industrial sectors such as high-end projectors and displays, food-sorting, digital printing, automotive, manufacturing industry, datacom; and lighting. Since 2007 the VUB B-PHOT team has the “Methusalem” label of research excellence and “Spearhead for Industrial Valorization” special status, both awarded by the Flemish government for its excellent track record in fundamental and applied research, and its outstanding industrial research validation, knowledge transfer, and entrepreneurship respectively.

Queen’s University Belfast (QUB)

Queen’s University Belfast (QUB) is a member of the Russell Group of the top 24 research active universities in the UK and has over 25,000 full and part time students. The Centre for Cancer Research & Cell Biology (CCRCB) is part of the School of Medicine, Dentistry and Biomedical Sciences of Queen’s University Belfast. It is a cross faculty and multi-disciplinary centre with over 300 clinical and basic researchers working in cancer and cell biology related areas from basic research through to translational and clinical application with a focus on personalised cancer medicine. It has a strong background in mechanistic studies of new targeted agents, through translational and clinical projects. It is closely aligned to the Northern Ireland Clinical Cancer Centre situated on the same campus and also has strong collaborative links with researchers in the school of Pharmacy, Physics and Biological Sciences. Radiation Science is a key focus area of the Centre bringing together multidisciplinary strengths in Radiation Physics, Biology and Oncology focused on clinical advances in radiotherapy including research on radiation risk. This is delivered through an Advanced Radiotherapy Group consisting of radiation biologists, radiotherapy physicists and radiation oncologists.


Università degli Studi dell’Insubria (UNINS)

Università degli Studi dell’Insubria, established in 1998, is a research oriented institution based in Varese and Como, in the northern part of Italy. Varese hosts the faculties of Economics, Medical Science, Biology/Biotechnology, Civil Engineering and Computer Science while the hard core science (Chemistry, Physics and Mathematics), Environmental science and the School of Law are located in Como.


By the time of writing, about 12 000 students at undergraduate and master level are enrolled at UNINS and the graduate school offers courses & research activities in the major fields to about 150 Ph.D. candidates, the majority of which are financially benefitting from scholarships by the University.


The scientific person in charge for the ORIGIN project is part of the Department of Science and High Technology, house of Chemists, Physicists and Mathematicians. The Dept. has a long standing tradition in participating and leading EU funded projects in different domains since the Framework Program 5; projects in cooperation with national and international companies are also key to the activities of the research staff at the Dept.


Galway Clinic (GC)

The Galway Clinic is a state of the art hospital which provides 24 hour health care services. There are in excess of 120 Physicians and Surgeons who have admitting and operating privileges and some have Consultant Suites within the Clinic. The Clinic has an occupancy rate of 95% and an average length of stay of 3.6 days. It has 146 in-patient beds; eight of which are ICU beds and the remaining 138 are on five in-patient units (Mother Teresa Unit, O’Malley Unit, Freyer Unit, John Paul II Unit and Our Lady of Knock Unit). There is a Same Day Surgery unit and Emergency Room. There are seven operating suites, an endoscopy suite, a catheterisation laboratory and an oncology day unit. Diagnostic modalities include CT, PET/CT, and MRI among others. The project will be hosted by the Department of Medical Physics at the Galway Clinic.

Screen Shot 2021-08-25 at 8.58.45 AM

BEBIG Medical

BEBIG Medical is a European-based medical device company which was founded in Oct. 2020 as a spin-off from Eckert & Ziegler BEBIG. Its core business will be the production and distribution of HDR brachytherapy equipment for the treat­ment of various cancer types such as prostate, gynecological, breast, esophagus, bronchus, and head & neck cancers. Until all relevant certificates related to the HDR manufacturing and distribution are transferred to BEBIG Medical, both companies, Eckert & Ziegler BEBIG and BEBIG Medical will jointly manufacture and distribute HDR brachytherapy equipment to their customer base, with Eckert & Ziegler BEBIG being the “legal” manufacturer. BEBIG Medicals headquarters and production facilities are in Germany and the USA. It has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company’s products and equipment are intended for use by oncologists, radiotherapists, medical specialists, and medical physicists. BEBIG Medical employs approximately 45 people. BEBIG Medical has taken over the partnership with the company PTW and will provide the PTW in-vivo dosimetry system as integrated solution for HDR brachytherapy until improved technologies such as the ORIGIN system are market ready. Hence, BEBIG Medical has commercial and technical expertise in integrating in-vivo dosimetry solution and a commercial interest to market the solution. BEBIG Medical took over from Eckert & Ziegler BEBIG as a member of the ORIGIN project consortium on January 1st 2021
LOGO FINBA transparent background
Updated Logo_HUCA_transparent background


The Foundation for Biosanitary Research and Innovation of the Principality of Asturias (FINBA) is a non-profit organisation configured as the management structure for Research, Development and Innovation activities in the health centres of the Health Service of the Principality of Asturias (SESPA). In 2016, Principado de Asturias, Servico de Salud del Principado de Asturias (SESPA), Universidad de Oviedo and FINBA signed a Cooperation Agreement to create the Instituto de Investigación Sanitaria del Principado de Asturias (ISPA). ISPA lacks its own legal personality, so the legal acts necessary to achieve its purposes are adopted by the FINBA, who act as the management body of the same, without prejudice to the competences of each of the associated institutions. The Hospital Universitario Central de Asturias (HUCA) is the reference hospital for the cancer treatment in the Principality of Asturias and is a member of ISPA.

  • – The Radiotherapy Department within HUCA is equipped with the following machines:
  • – Four LINAC (Varian) with VMAT technology and EPID transit dosimetry for invivo dosimetry in the four linacs
  • – One INTRABEAM 600
  • – Two afterloaders HDR SagiNova with Co-60 sources (Eckert&Ziegler).

The Radiotherapy Department has treated 2200 patients in 2020 year with external radiotherapy and 350 patients with HDR and LDR seeds (about 60 year with this technique).  Since 2014 invivo dosimetry has been performed in all HDR prostate patients, performing more than 400 determinations to date.-